M3 Biotechnology, Inc. logo

M3 Biotechnology, Inc.

M3 is a clinical stage biopharmaceutical company focused on development of therapeutics to address Alzheimer's, Parkinson's and Neurodegeneration. M3 Biotechnology is a start-up company, focused on the development of small molecule, peptide and peptidomimetic modulators of growth factor/neurotrophic factor systems for the treatment of neurodegenerative disease.

M3 Biotechnology is based out of the researches conducted by its founders Leen Kawas PhD, Joseph Harding, PhD, John (Jay) Wright, PhD.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://m3bio.com
Founded2011
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
CoMotion Labs @ Fluke Hall4000 Mason Rd Suite 300, Box 352141, WA 98195-2141
Seattle
United States
Email
Contact Number
+1 150-933-95620
+1 206-221-8112

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/m3-biotechnology” connections=”true” suffix=””]

Nov 2017, M3 Biotechnology raises $15.2M investments from Seattle biotech veteran Bruce Montgomery and his brother Michael Montgomery include Dolby Family Ventures, the Alzheimers Drug Discovery Fund, WFund and Kayne Capital.

In April 2017, Alzheimers Drug Discovery Foundation grant a second investment of $1.4 million to M3 Biotechnology

In Feb 2016, M3 Biotechnology raise $10 Mn in its Series A Round led by Montgomery brothers, W-Fund and WRF Capital. The funds will be used to advance its lead compound MM-201 to enter into clinical trials.